secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001370053-23-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio reports FY2022 net loss $128.7M; cash $584.2M; initiates Phase 2b trials for rosnilimab and ANB032
--------------------------------------------------------------------------------

- Net loss for Q4 2022 was $26.4M ($0.93 per share); full year net loss $128.7M ($4.57 per share), compared to $57.8M in 2021.
- Cash, cash equivalents and investments totaled $584.2M as of Dec 31, 2022; cash runway through year-end 2026 reiterated.
- Initiating global Phase 2b trial for rosnilimab (PD-1 agonist) in RA in Q3 2023; second Phase 2 trial in another indication by year-end 2023.
- Initiating global Phase 2b trial for ANB032 (BTLA agonist) in atopic dermatitis in Q2 2023; top-line data expected year-end 2024.
- Board authorized $50M stock repurchase plan in January 2023, expiring Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/0001370053-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005323000019/anab-20230301.htm
  HTML page:      https://secwatch.observer/filing/0001370053-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer